Mode
Text Size
Log in / Sign up

Meta-analysis of efruxifermin shows significant liver benefits in NASH/MASH patients with short follow-upNew Drug Clears Fat and Scar From Liver

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note higher GI adverse events and short follow-up in this meta-analysis of efruxifermin for NASH/MASH.

This systematic review and meta-analysis assessed the efficacy and safety of efruxifermin compared with placebo in patients with NASH/MASH. The analysis included data from 419 participants, though the number of included RCTs was limited and the follow-up duration was short.

Key findings indicated a significant advantage for efruxifermin regarding liver outcomes. Specifically, there was a significant advantage for achieving at least one stage improvement in liver fibrosis without worsening steatohepatitis (RR: 2.18; 95% CI [1.34, 3.57], P = 0.002). The drug also showed significant advantages for NASH/MASH resolution with fibrosis improvement (RR: 5.15; 95% CI [1.52, 17.47], P = 0.009) and at least two-point NAS improvement without fibrosis worsening (RR: 3.34; 95% CI [1.93, 5.80], P < 0.001).

Significant increases in proportions were observed for hepatic fat fraction reductions, including at least 30% reduction (RR: 4.69; 95% CI [2.53, 8.71], P < 0.001), at least 50% reduction (RR: 22.57; 95% CI [5.78, 88.22], P < 0.001), and liver fat normalization (RR: 13.03; 95% CI [3.30, 51.50], P < 0.001). Safety assessments noted higher rates of gastrointestinal adverse events and discontinuations, while serious adverse events were not reported.

The authors note that practice relevance is not reported and that causality should be interpreted with caution given the study limitations.

Imagine waking up with a heavy feeling in your belly that won't go away. For millions of people, this isn't just bloating. It is a sign of a serious condition called fatty liver disease.

Now, a new treatment called efruxifermin shows it might help clear that fat and even repair the scar tissue inside your liver.

Fatty liver disease is becoming very common. It happens when too much fat builds up in your liver. Over time, this fat can turn into inflammation and scarring. Doctors call this scarring fibrosis.

If left untreated, fibrosis can lead to serious liver problems. The biggest frustration for patients is that there are not many good options yet. Most treatments focus only on losing weight. But what if you need help fixing the damage directly?

The surprising shift

For years, doctors have told patients that lifestyle changes are the only real fix. This meant diet and exercise were the only tools in the toolbox.

But here is the twist. A new analysis of recent trials suggests a powerful new tool is ready. This drug doesn't just help you lose weight. It actively works to remove fat and stop the scarring process.

Think of your liver like a busy factory. When too much fat gets in, the factory slows down and starts to break. This causes the scarring we fear.

Efruxifermin acts like a master key. It unlocks the cells that store fat and tells them to release it. It also helps stop the signals that cause scarring to form.

It is like clearing a traffic jam on a highway. The cars (fat) get out of the way, and the road (your liver) can heal itself again.

Researchers looked at four different studies involving 419 people. These were high-quality tests where some people got the new drug and others got a fake pill.

The tests lasted for a specific period to see if the drug worked safely. They checked liver scans, blood tests, and how patients felt.

The results were very clear. People taking efruxifermin saw much better results than those on the fake pill.

The drug helped improve the scarring in the liver. More than twice as many people in the drug group saw their scarring get better compared to the placebo group.

It also helped remove fat very quickly. Many patients saw their liver fat drop by over half. Some even reached a point where their liver looked normal on scans.

This doesn't mean this treatment is available yet.

While the results are exciting, we must be careful. The drug did cause some side effects. Some people had stomach issues like nausea or pain. A few people had to stop taking the drug because of these problems.

Doctors see this as a big step forward. It fits right into the plan to treat the root cause of the disease.

However, experts say we need more data. We need to know if it works for everyone, not just the people in these specific studies.

If you have fatty liver disease, this news is hopeful. It means new options are coming soon.

You should talk to your doctor about your current treatment plan. Ask if you are a candidate for future trials.

Do not stop your current diet or exercise routine. These are still the foundation of health. This new drug is meant to work alongside them, not replace them.

We must be honest about the limits of this research. The studies were relatively small. They only included 419 people total.

Also, the tests were not very long. We do not know yet if the benefits last for years. We also do not know if it works for everyone with different types of liver disease.

More large studies are needed. Scientists will run bigger tests with more people. They will watch patients for longer periods to check for long-term safety.

Regulators will review all the data before approving the drug for general use. This process takes time to ensure patient safety.

Until then, keep focusing on healthy habits. Stay hopeful for the new tools coming down the pipeline. Your liver deserves the best care possible.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
AimsEfruxifermin is a promising treatment for non-alcoholic steatohepatitis (NASH), now referred to as metabolic dysfunction-associated steatohepatitis (MASH). This meta-analysis aims to evaluate the efficacy and safety of efruxifermin in patients with NASH/MASH.MethodsWe systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of efruxifermin in patients with NASH/MASH up to 6 August 2025. The primary outcomes were changes in liver fibrosis and steatosis, with safety assessed through adverse events.ResultsThis meta-analysis included 4 RCTs with 419 participants. Compared with placebo, efruxifermin demonstrated a significant advantage in ≥1 stage improvement in liver fibrosis without worsening steatohepatitis (relative risk [RR]: 2.18, 95% confidence interval [CI] [1.34, 3.57], P = 0.002), NASH/MASH resolution with fibrosis improvement (RR: 5.15, 95% CI [1.52, 17.47], P = 0.009), and ≥2-point non-alcoholic fatty liver disease activity score (NAS) improvement without fibrosis worsening (RR: 3.34, 95% CI [1.93, 5.80], P < 0.001). Additionally, efruxifermin reduced the enhanced liver fibrosis (ELF) score, liver stiffness measurement (LSM), and serum levels of N-terminal type-III collagen pro-peptide (ProC3). For steatosis reduction, efruxifermin significantly increased the proportions of patients with ≥30% hepatic fat fraction (HFF) reduction (RR: 4.69, 95% CI [2.53, 8.71], P < 0.001), ≥50% HFF reduction (RR: 22.57, 95% CI [5.78, 88.22], P < 0.001), and liver fat normalization (RR: 13.03, 95% CI [3.30, 51.50], P < 0.001). However, efruxifermin treatment was associated with higher rates of both adverse events leading to discontinuation and gastrointestinal adverse events.ConclusionEfruxifermin may represent a promising therapeutic option for NASH/MASH. Given the limitations in both the number and short follow-up duration of the included RCTs, the conclusions should be interpreted with caution. Further large-scale, multicenter, long-term, and high-quality RCTs are necessary to validate these results in diverse populations.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42025111 4840.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.